Cargando…

Development of Glucose Transporter (GLUT) Inhibitors

The discovery of novel compound classes endowed with biological activity is at the heart of chemical biology and medicinal chemistry research. This enables novel biological insights and inspires new approaches to the treatment of diseases. Cancer cells frequently exhibit altered glycolysis and gluco...

Descripción completa

Detalles Bibliográficos
Autores principales: Reckzeh, Elena S., Waldmann, Herbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217229/
https://www.ncbi.nlm.nih.gov/pubmed/32421048
http://dx.doi.org/10.1002/ejoc.201901353
_version_ 1783532575675908096
author Reckzeh, Elena S.
Waldmann, Herbert
author_facet Reckzeh, Elena S.
Waldmann, Herbert
author_sort Reckzeh, Elena S.
collection PubMed
description The discovery of novel compound classes endowed with biological activity is at the heart of chemical biology and medicinal chemistry research. This enables novel biological insights and inspires new approaches to the treatment of diseases. Cancer cells frequently exhibit altered glycolysis and glucose metabolism and an increased glucose demand. Thus, targeting glucose uptake and metabolism may open up novel opportunities for the discovery of compounds that differentiate between normal and malignant cells. This review discusses the different chemical approaches to the development of novel inhibitors of glucose uptake through facilitative glucose transporters (GLUTs), and focusses on the most advanced and potent inhibitor classes known to date. GLUT inhibitors may find application not only in the treatment of cancer, but also of other proliferative diseases that exhibit glucose addiction.
format Online
Article
Text
id pubmed-7217229
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72172292020-05-13 Development of Glucose Transporter (GLUT) Inhibitors Reckzeh, Elena S. Waldmann, Herbert European J Org Chem Minireviews The discovery of novel compound classes endowed with biological activity is at the heart of chemical biology and medicinal chemistry research. This enables novel biological insights and inspires new approaches to the treatment of diseases. Cancer cells frequently exhibit altered glycolysis and glucose metabolism and an increased glucose demand. Thus, targeting glucose uptake and metabolism may open up novel opportunities for the discovery of compounds that differentiate between normal and malignant cells. This review discusses the different chemical approaches to the development of novel inhibitors of glucose uptake through facilitative glucose transporters (GLUTs), and focusses on the most advanced and potent inhibitor classes known to date. GLUT inhibitors may find application not only in the treatment of cancer, but also of other proliferative diseases that exhibit glucose addiction. John Wiley and Sons Inc. 2019-11-28 2020-05-03 /pmc/articles/PMC7217229/ /pubmed/32421048 http://dx.doi.org/10.1002/ejoc.201901353 Text en © 2019 The Authors. Published by Wiley‐VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Minireviews
Reckzeh, Elena S.
Waldmann, Herbert
Development of Glucose Transporter (GLUT) Inhibitors
title Development of Glucose Transporter (GLUT) Inhibitors
title_full Development of Glucose Transporter (GLUT) Inhibitors
title_fullStr Development of Glucose Transporter (GLUT) Inhibitors
title_full_unstemmed Development of Glucose Transporter (GLUT) Inhibitors
title_short Development of Glucose Transporter (GLUT) Inhibitors
title_sort development of glucose transporter (glut) inhibitors
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217229/
https://www.ncbi.nlm.nih.gov/pubmed/32421048
http://dx.doi.org/10.1002/ejoc.201901353
work_keys_str_mv AT reckzehelenas developmentofglucosetransporterglutinhibitors
AT waldmannherbert developmentofglucosetransporterglutinhibitors